USP compliance <661> and Total Organic Carbon (TOC) analysis

The pharmaceutical industry relies heavily on plastic packaging to market its products. It must be demonstrated that packaging materials and their manufacturing materials do not interact with therapeutic products in such a way as to alter their suitability for use. The USP chapter has recently been revised to broaden its scope. This has allowed the regulation to cover separately the materials used in packaging and the packaging system (which may comprise several materials).
Read Application Note